Although it has been well documented that SREBPs are the key regulators of HMGCR gene41, there were no significant increase in the expression of SREBP1 and 2 genes in CTL-refractory P3 tumor cells and NR to anti-PD-1 therapy compared to P0 tumor cells and R to anti-PD-1 therapy, respectively (Supplementary Fig 11). This evidence concerns the gene SREBF1 and neoplasm.